

**Curriculum Vitae**  
**Alexandre A. Petrakian, MD, FACC**

**Practice**

---

2009-Present Tyler Cardiac and Endovascular Center  
1769 Troup Hwy, Tyler, Texas

2000-Present Cardiovascular Associates of East Texas, P.A., Tyler, Texas

**Affiliation**

---

2000-Present CAET - Research  
1761 Troup Hwy, Tyler, Texas

1/1/13-4/26/13 TAD Clinical Research  
1741 Troup Hwy, Tyler, Texas

**Education**

---

**Post-Graduate Training**

Cardiac Electrophysiology Fellowship  
1999-2000 Baylor College of Medicine Houston, TX

Cardiology Fellowship  
1996-1999 Baylor College of Medicine Houston, TX

Internal Medicine Residency  
1993-1996 Baylor College of Medicine Houston, TX

Academic Degrees

1989-1993 American University of Beirut Beirut, Lebanon  
Doctor of Medicine

1986-1989 American University of Beirut Beirut, Lebanon  
Bachelor of Sciences in Biology with distinction

1971-1986 College Louise Wegmann Beirut, Lebanon  
French Baccaureate with Honors

## **Board Certification**

---

1999, 2009 American Board of Internal Medicine – Cardiovascular Diseases  
1993 Education Commission for Foreign Medical Graduates (ECFMG)

## **Licensure**

---

2001 Nuclear Radiation Certification State of Texas #L04800  
1997 Texas State Board of Medical Examiners K6234

## **Hospital Appointments**

---

Trinity Mother Frances Hospital, Tyler, Texas  
East Texas Medical Center Hospital, Tyler, Texas  
East Texas Medical Center, Carthage, Texas  
Texas Spine and Joint Hospital, Tyler, Texas

## **Professional Societies and Other Memberships**

---

Fellow, American College of Cardiology  
Diplomate of the American Board of Internal Medicine  
Diplomate of the American Board of Internal Medicine-Cardiology  
Diplomate of the American Board of Internal Medicine – Cardiac Electrophysiology

## **Research**

---

Co-Investigator – ODYSSEY - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome.

Co-Investigator – CAMELLIA - A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment with BELVIQ (lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects with Cardiovascular Disease or Multiple Cardiovascular Risk Factors.

ANALYZE ST - Monitoring to Detect ACS Events in ICD Patients (Analyze ST)

Co-Investigator – LSS 4 SITE - The Longitudinal Surveillance Study of the 4-SITE Lead/Header System

Co-Investigator – INGEVITY - Active Fixation and Passive Fixation Pace/Sense Lead Clinical Study

Co-Investigator – DECLARE - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes.

Co-Investigator – ABSORB III - Randomized Controlled Trial. A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the treatment of Subjects with de novo Native coronary Artery Lesions.

Co-Investigator – AD HOC PCI - A randomized, open-label, multiple-center, parallel group, study to compare the platelet inhibition with Verify Now™ assay of ticagrelor vs. clopidogrel in troponin negative Acute Coronary Syndrome (ACS) subjects undergoing Ad Hoc percutaneous coronary intervention (PCI)

Co-Investigator – EXCITE - Excimer laser randomized Controlled study for treatment of femoropopliteal In-Stent Restenosis.

Co-Investigator – EUCLID -A randomized, double-blind, parallel group, multicenter phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischemic stroke in patients with established Peripheral Artery Disease (EUCLID – Examining Use of tiCagreLor In paD)

Co-Investigator – Paradigm - A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction.

Primary Investigator - RATE Registry – Registry of AT/AF Episodes in the CRM Device Population.

Primary Investigator – CRT RENEWAL Registry - “Cardiac Resynchronization Therapy Registry Evaluating Patient Response with RENEWAL Family Devices (CRT RENEWAL Registry)”

Primary Investigator – ACT Registry - A prospective, outcome-oriented registry of all patients implanted with an SJM ICD and to evaluate the utilization of advanced features in patients with current ICD indications.

Primary Investigator – OMNI Study - Post-market observational study conducted in the United states. The purpose of the OMNI study is to characterize therapy and diagnostic utilization in study participants implanted with study devices and to describe ICD therapy utilization for life threatening arrhythmias in primary and secondary prevention study participants.

Primary Investigator – PEGASUS Study – “Pacing Evaluation – Atrial Support Study in Cardiac Resynchronization Therapy” (PEGASUS CRT Study)

Co-Investigator – OPTIMUM Registry - A prospective, outcome-oriented registry of patients implanted with SJM Optim™ leads. This registry evaluated the chronic performance of the market-released SJM Cardiac Rhythm Management (CRM) leads with Optim™ insulation material.

Co-Investigator – RE-LY - **R**andomized **E**valuation of **L**ong term anticoagulant therapy (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non-inferiority trial.

Co-Investigator – ASPEN - ASPEN --“AF Suppression Pacing to Prevent First Episode of Atrial Fibrillation in High Risk Patients”-- Study.

Co-Investigator – ENDEAVOR IV – A Randomized, Controlled Trial of the Medtronic Endeavor Drug Eluting Coronary Stent System versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions.

Co-Investigator – A-HeFT - A Placebo-Controlled Trial of Bidil Added to Standard Therapy In African-American Patients with Heart Failure.

Co-Investigator – TRENDS - A prospective, non-randomized, multi-center trial in subjects implanted with a commercially available Medtronic implantable pulse generator (IPG), implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) device. The primary purpose of the trial is to determine if the device trending data are indicators of clinical outcomes in subjects with atrial tachyarrhythmias.

Co-Investigator – ACCOMPLISH - A prospective, multicenter, double-blind, randomized, active-controlled trial to compare the effects of Lotrel (amlodipine/benazepril to benazepril and hydrochlorothiazide combined on the reduction of cardiovascular morbidity and mortality in patients with high risk hypertension.

Co-Investigator - AMIHOT II – A prospective, Multi-center, randomized study of Aqueous Oxygen Therapy for 90 minutes in Anterior Acute MI patients with successful PCI/stenting presenting within 6 hours from time of symptom onset until time of reperfusion.

Co-Investigator – TIMI38/TRITON – A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Patients who are to Undergo Percutaneous Coronary Intervention; a Phase III, multicenter, randomized, parallel-group, double-dummy, active controlled trial in patients with acute coronary syndrome (ACS), who are to undergo percutaneous coronary intervention (PCI).

Co-Investigator - ULTRA study- Ventricular Automatic Capture assessment Study.

Co-Investigator – VISION 305 - “Vasodilator Induced Stress In Concordance with Adenosine” A multicenter, risk-stratified, randomized, double-blind, double-dummy study drug administration, active-controlled, complete two-arm crossover study with a reference third arm.

Co-Investigator - APEX-AMI - “A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of Pexelizumab in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.” (Assessment of PEXelizumab in Acute Myocardial Infarction)-APEX-AMI.

Investigator - ASSIST – Atrial Tachyarrhythmia Suppression Strategy in ICD Subjects Trial

Investigator - RIATA – Evaluation of Riata Integrated and Dedicated Bipolar Leads with CRT devices.

Investigator—MAVRIC-- MARquis/Maximo VR ICD Programming Practices Registry

Investigator- MASTER-- Microvolt T Wave Alternans S Testing for Risk Stratifcation of Post MI Patients

Investigator – WAVE –World wide application study of Marquis VR enhancements. A global prospective, non-randomized, multicenter trial that focuses on the wavelet dynamic discrimination criterion by use of the Marquis VR model 7230 implantable cardioverter defibrillator (ICD).

Investigator – VAST – Ventricular arrhythmia suppression trial. A randomized, single-blinded, crossover, comparative trial of the rate smoothing feature. Of Guidant Prism and Prism II Automatic implantable cardio defibrillator.

Participant - ALIVE – The Azimilide Post - infarct Survival Evaluation

Participant - PURSUIT – Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy

Participant – AFFIRM – Atrial Fibrillation Follow-up Investigation of Rhythm Management

Co-Investigator - A prospective, non-randomized, multi-center trial in subjects implanted with a commercially available Medtronic implantable pulse generator (IPG), implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) device. The primary purpose of the trial is to determine if the device trending data are indicators of clinical outcomes in subjects with atrial tachyarrhythmias.

Co-Investigator - ACUITY Trial- A randomized comparison of Angiomax (bivalirudin) versus Lovenox/Clexane (enoxaparin) in patients undergoing early invasive management for acute coronary syndrome with our ST-segment elevation.

Co-Investigator- AWARE- Analysis of a New AT/AF Detection Algorithm in Patients with Atrial Arrhythmias.

Co-Investigator - LESS - Lower Energy Safety Study

Co-Investigator - GUSTO IV AMI (Protocol CO116T31): A Phase III, randomized, open-label trial evaluating the efficacy and safety of. ReoPro™ (ABCIXIMAB) in combination with reduced dose Retavase™/Rapilysin™ (Recombinant Plasminogen Activator, Reteplase, r-PA) for the treatment of acute myocardial infarction.

Co-Investigator - AMISTAD II Trial (Phase III): A randomized, double-blind, placebo-controlled, multicenter trial to evaluate the efficacy and safety of Adenosine (Pallacor, Adenosine Injection) as an adjunct to reperfusion therapy (Thrombolysis or Mechanical Reperfusion) in the treatment of acute anterolateral myocardial infarction.

Co-Investigator - VALIANT Trial Phase III (VALsartan In Acute myocardial iNfarcTion): A multinational, multicenter, double-blind, randomized, active controlled, parallel group study comparing the efficacy and safety of long-term treatment with Valsartan, Captopril and their combination in high risk patients after myocardial infarction.

Co-Investigator – VALIANT REGISTRY SUBSTUDY : VALIANT Trial Phase III (VALsartan In Acute myocardial iNfarcTion): A multinational, multicenter, double-blind, randomized, active controlled, parallel group study comparing the efficacy and safety of long-term treatment with Valsartan, Captopril and their combination in high risk patients after myocardial infarction.

Co-Investigator – EPHESUS – IE-99-02-035, Clinical protocol for a double blind, randomized, placebo-controlled trial to evaluating the safety and efficacy of eplerenone in patients with heart failure following acute myocardial infarction

Co-Investigator - OCTAVE - CV137-120 Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril (OCTAVE) A Phase III, Randomized, Double Blind, Active Controlled Comparison of Omapatrilat and Enalapril in Subjects with newly Diagnosed or Established Hypertension

Co-Investigator – REPLACE – TMC-BIV-00-01, Randomized Evaluation in Percutaneous Coronary Intervention Linking Angiomax to Reduced Clinical Events.

Co-Investigator - REPLACE II - A Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events, Part 2: REPLACE-2 (TMC-BIV-01-03)

Co-Investigator – SYNERGY- A Prospective, Randomized, Open-Label, Multicenter Study in Patients Presenting with Acute Coronary Syndromes  
Aventix Pharmaceuticals Protocol Number ENO.GMA.301.IND# 31532

Co-Investigator – A Double-Blind Comparison Of The Incidence Of Hypotension With Two Formulations Of Intravenous Amiodarone: Cordarone® I.V. vs Amiodarone Aqueous I.V. Injection - Protocol No. 058K1-312-US

Co-Investigator – CRISP - A single Arm, Open label Study of Cervastatin (Baycol®) in Community based Patients with Hypercholesterolemia at risk for Cardiovascular Disease and patients with Cardiovascular Disease. To Monitor inflammatory markers

Co-Investigator-INSPIRE :A Randomized, Prospective Multicenter Trial Evaluating The Role Of Adenosine Tc99m Sestamibi SinglePhoton Emission Computed Tomography For Assessing Risk And Therapeutic Outcomes In Survivors Of Acute Myocardial Infarction.

Co-Investigator – Otsuka Protocol 21-98-214-01 CASTLE “ A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Arm, Study to Asses The Long-Term Effects of Pletal® (Cilostazol) Versus Placebo Administered Orally to Patients with Intermittent Claudication Secondary to Peripheral Arterial Disease”.

Co-Investigator – AMIHOT – TherOx Aqueous Oxygen System – Acute Myocardial Infarction with Hyperoxemic Therapy “AMIHOT” Phase II clinical trial. A Randomized, Controlled, Multicenter Trial of Aqueous Oxygen Infusion for 90 Minutes Post-Primary PTCA/Stent Intervention in Acute Myocardial Infarction Patients.

Co-Investigator - Extra Point. Protocol # S1710202. Cardiovascular Safety Study of Nicotine Transdermal System.

Co-Investigator - XIENCE™ V: Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study sponsored by Abbott Vascular Inc.

Investigator - Quick FLEX Model 1258T Left Heart Pacing Lead Post Approval Study

Investigator - ST Monitoring to Detect ACS Events in ICD Patients (Analyze ST)

Co-Investigator - Taxus Libertē “A prospective, multi-center study designed to observe clinical outcomes in patient receiving the TAXUS Libertē-Paclitaxel-Eluting Coronary Stent and prasugrel as part of a dual antiplatelet therapy drug regimen”

Co-Investigator - RESOLUTE US: “A Clinical Evaluation of the Medtronic Endeavor® Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of *De Novo* Lesions in Native Coronary Arteries with a Reference Vessel Diameter of 2.25 mm to 4.2 mm.”

Co-Investigator - ENDEAVOR SVS Registry: “A Clinical Evaluation of the Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment of Single *De novo* Lesions in Small Diameter Native Coronary Arteries”

Co-Investigator - TAO: “A randomized, double-blind, triple-dummy trial to compare the efficacy of otamixaban with Unfractionated Heparin + eptifibatide, in patients with Unstable angina/Non ST segment Elevation Myocardial infarction scheduled to undergo an early invasive strategy”

Co-Investigator - VISTA-16 Evaluation of the Safety and Efficacy of Short-term A-002 Treatment in Subjects with Acute Coronary Syndromes.

Co-Investigator - IMPROVE IT - A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial.